Nima Farzan, Kinnate Biopharma CEO

Kin­nate Bio­phar­ma touts ear­ly ef­fi­ca­cy in pan-RAF pro­gram: #AACR23

OR­LAN­DO — Af­ter suf­fer­ing two de­lays last year, Kin­nate Bio­phar­ma is of­fer­ing an ear­ly-stage look at its monother­a­py pan-RAF in­hibitor, while de­pri­or­i­tiz­ing a pre­clin­i­cal pro­gram to …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.